Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

GSK plc GSK announced plans ... out-of-pocket expenses for all its inhaler products at $35 per month, also beginning in June. Boehringer’s inhaled respiratory portfolio includes Atrovent ...

GSK (GSK.L), opens new tab on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the ...

GSK's next-generation respiratory drugs and HIV drugs look ... % over the next five years (including joint ventures), with new products such as Shingrix and Arexvy offsetting generic competition ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

These products broadly target infectious diseases, HIV, respiratory and immunology, oncology, and other smaller "opportunity-driven" IPs. In my view, you can think of GSK as a company with a set ...